Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · Real-Time Price · USD
6.67
+0.23 (3.57%)
At close: Aug 21, 2026, 4:00 PM EDT
6.67
0.00 (0.04%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 82 employees as of December 31, 2025. The number of employees increased by 12 or 17.14% compared to the previous year.
Employees
82
Change (1Y)
12
Growth (1Y)
17.14%
Revenue / Employee
$384,366
Profits / Employee
-$926,366
Market Cap
41.65M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 82 | 12 | 17.14% |
| Dec 31, 2024 | 70 | 4 | 6.06% |
| Sep 30, 2024 | 68 | 0 | - |
| Jun 30, 2024 | 68 | 0 | - |
| Mar 31, 2024 | 67 | -2 | -2.90% |
| Dec 31, 2023 | 66 | -17 | -20.48% |
| Sep 30, 2023 | 68 | -21 | -23.60% |
| Jun 30, 2023 | 68 | -21 | -23.60% |
| Mar 31, 2023 | 69 | -26 | -27.37% |
| Dec 31, 2022 | 83 | -10 | -10.75% |
| Sep 30, 2022 | 89 | 3 | 3.49% |
| Jun 30, 2022 | 89 | 3 | 3.49% |
| Mar 31, 2022 | 95 | 26 | 37.68% |
| Dec 31, 2021 | 93 | 19 | 25.68% |
| Sep 30, 2021 | 86 | 13 | 17.81% |
| Jun 30, 2021 | 86 | 19 | 28.36% |
| Mar 31, 2021 | 69 | 8 | 13.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Metagenomi Therapeutics | 113 |
| Alps Group | 93 |
| Seres Therapeutics | 66 |
| Actinium Pharmaceuticals | 27 |
| Veru Inc. | 20 |
| Filana Therapeutics | 20 |
| Edesa Biotech | 17 |
ALGS News
- 8 days ago - Aligos Therapeutics Slides: Corporate presentation - Filings
- 9 days ago - Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China - GlobeNewsWire
- 15 days ago - Aligos Therapeutics Earnings release: Q2 2026 - Filings
- 15 days ago - Aligos Therapeutics Quarterly report: Q2 2026 - Filings
- 15 days ago - Aligos Therapeutics reports Q2 EPS (14c), consensus ($1.38) - TheFly
- 22 days ago - Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026 - GlobeNewsWire
- 5 weeks ago - Aligos Therapeutics completes enrollment in B-SUPREME study - TheFly
- 5 weeks ago - Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection - GlobeNewsWire